FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer FDA OKs Elacestrant for ESR1+ Advanced, Metastatic Breast Cancer

The phase 3 data showed a 2-month progression-free survival benefit with elacestrant versus fulvestrant or an aromatase inhibitor.Medscape Medical News

Source: Medscape Hematology-Oncology Headlines - January 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news